Most pharma companies have climate commitments. Far fewer have woven those standards into how they select, onboard, and work with suppliers. At the PSCI Decarbonization Summit 2025, Koen Postuma, Director of Procurement at Merck, Vincent Barbotin, Scope 3 Active Ingredient
At Nordic Life Science Days (NLSDays), Microsoft and Cegeka explored how pharmaceutical companies can adopt AI-powered automation while maintaining regulatory compliance. The workshop covered practical applications of AI agents already in production, compliance-ready ERP implementation strategies, and the business case
FAMAR, a contract development and manufacturing organisation (CDMO), has upgraded its high-potency capabilities with the installation of the MG2 FlexaLAB OEB5 continuous motion capsule filler at its R&D facility. The system is designed to meet OEB5 containment requirements and is
Naobios, a contract development and manufacturing organisation (CDMO), has announced a collaboration with the Tokyo Metropolitan Institute of Medical Science (TMIMS) to develop a new vaccine for mpox, also known as monkeypox. The vaccine will be based on a non-replicating
Abolis Biotechnologies, a specialist in industrial solutions using microorganisms, has announced a strategic collaboration with EUROAPI, a leading producer of active pharmaceutical ingredients, to develop microbial strains for synthesising key intermediates and 20 active ingredients, particularly corticosteroids. The agreement forms
AGC Biologics, a global CDMO specialising in cell and gene therapies, has entered into an agreement with Rarity PBC to deliver end-to-end development and GMP manufacturing for Rarity’s RDP-101 therapy, designed for Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID). The gene
SK pharmteco, a global contract development and manufacturing organization (CDMO), has announced a $6.1 million investment to expand its Rancho Cordova, California, facility. The funding will establish a new laboratory and CGMP-kilo-scale facility dedicated to Solid-Phase Peptide Synthesis (SPPS) and
Laurus Labs, the Hyderabad-based pharmaceutical and contract development and manufacturing organisation (CDMO), reported a substantial increase in its consolidated net profit for the second quarter ended September 2025. Profit jumped to ₹195 crore, compared with ₹20 crore in the same
Aenova has announced a major investment in its sterile biologics manufacturing capabilities with the installation of an additional fill & finish (F&F) line at its Latina site, part of a €100 million expansion programme over the next three years. The
Syngene International, a global contract research, development and manufacturing organization (CRDMO), has announced the addition of a GMP bioconjugation suite at its Bengaluru commercial biologics facility (Unit 3). The new suite positions Syngene among a select group of CDMOs capable
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
